Wedbush Reaffirms Outperform Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by stock analysts at Wedbush in a report released on Friday,Benzinga reports. They currently have a $45.00 price target on the stock. Wedbush’s price target indicates a potential upside of 12.50% from the stock’s previous close.

Several other brokerages also recently commented on ORKA. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. BTIG Research increased their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler started coverage on Oruka Therapeutics in a research note on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price objective for the company. Guggenheim restated a “buy” rating and set a $60.00 price objective on shares of Oruka Therapeutics in a report on Friday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Trading Up 25.0%

NASDAQ:ORKA opened at $40.00 on Friday. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -21.51 and a beta of -0.38. The firm has a fifty day simple moving average of $32.92 and a two-hundred day simple moving average of $27.59. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. Equities analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total transaction of $226,590.00. Following the transaction, the insider directly owned 34,018 shares of the company’s stock, valued at $1,101,162.66. The trade was a 17.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 21,000 shares of company stock worth $663,530. 24.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Financial Enhancement Group LLC bought a new stake in Oruka Therapeutics in the 3rd quarter worth about $631,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $296,000. Avoro Capital Advisors LLC bought a new position in shares of Oruka Therapeutics during the 3rd quarter worth approximately $25,640,000. B Group Inc. boosted its stake in shares of Oruka Therapeutics by 28.8% in the 2nd quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after buying an additional 16,785 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Oruka Therapeutics by 100.6% in the 2nd quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after buying an additional 354,821 shares during the last quarter. 56.44% of the stock is owned by institutional investors.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.